Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate PK Study in Lennox-Gastaut Syndrome
NCT03731715Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of carisbamate in Lennox-Gastaut syndrome (LGS) (4 cohorts), sponsored by SK Life Science, Inc. Primary endpoints: Area Under the Curve at Day 17 and Maximum Plasma Concentration at Day 17. Started Feb 2019; status: completed.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT03731715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731715.